Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) announced its participation in three investor conferences in September 2022. The events include the Citi Hong Kong China Corporate Day on September 20-21, the Cantor Oncology, Hematology & HemeOnc Conference on September 28, and the Jefferies Cell & Genetic Medicine Summit on September 30. Gracell is focused on developing innovative cell therapies for cancer treatment, employing advanced technologies like FasTCAR and TruUCAR. A webcast of the fireside chat at the Jefferies Summit will be available on their investor website for 30 days post-event.

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in September 2022 as follows:

Citi Hong Kong China Corporate Day – Virtual
One-on-one meetings: Tuesday, September 20, 2022 – Wednesday, September 21, 2022

Cantor Oncology, Hematology & HemeOnc Conference
Panel Presentation: Wednesday, September 28 at 4:15 p.m. ET
One-on-one meetings: Wednesday, September 28, 2022
Location: New York, NY

Jefferies Cell & Genetic Medicine Summit
Fireside Chat: Friday, September 30 at 2:00 p.m. ET
One-on-one meetings: Friday, September 30, 2022
Location: New York, NY

A webcast of the fireside chat will be available on the News and Events section of Gracell's investor website. A replay of the webcast will be available for 30 days following the event.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com and follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong 
gracie.tong@gracellbio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-three-upcoming-investor-conferences-301623784.html

SOURCE Gracell Biotechnologies Inc.

FAQ

What are the dates for Gracell's investor conferences in September 2022?

Gracell's investor conferences are scheduled for September 20-21 (Citi Hong Kong China Corporate Day), September 28 (Cantor Oncology Conference), and September 30 (Jefferies Cell & Genetic Medicine Summit).

What technology platforms does Gracell use for cancer therapies?

Gracell utilizes advanced technology platforms such as FasTCAR and TruUCAR in its development of cancer therapies.

Where can I watch the webcast from Gracell's September 30 fireside chat?

The webcast of Gracell's September 30 fireside chat will be available on their investor website for 30 days after the event.

What is Gracell Biotechnologies focused on developing?

Gracell Biotechnologies focuses on discovering and developing highly efficacious and affordable cell therapies for cancer treatment.

What time is Gracell's panel presentation at the Cantor Oncology Conference?

Gracell's panel presentation at the Cantor Oncology Conference is scheduled for September 28, 2022, at 4:15 p.m. ET.